11

May

2023

18:30

BST

19:30

CEST

13:30

EST

Webinar

Tricuspid Regurgitation: How Will Valve Repair Change Our Practice?

Average (ratings)
No ratings
Your rating

Overview

Severe tricuspid regurgitation remains an unmet need, given the adverse outcomes and symptom burden associated with it. It is estimated that >70 million people worldwide currently have some degree of tricuspid regurgitation. Until recently, surgical intervention and medical therapy were the main treatment modalities, however, transcatheter repair is now an option for many people – particularly where the risk associated with surgery is elevated.

This live broadcast, chaired by Prof Ralph Stephan von Bardeleben (Heart Valve Center, Mainz, DE), aims to bring the community up to date with the latest clinical data on tricuspid valve repair techniques and to identify those patients who stand to gain most benefit from repair-based approaches compared with surgery or medical therapy alone. 

 

Want to find out more about the recent TRILUMINATE Pivotal Trial Results? 

In this short series of interviews, our faculty discuss the recent TRILUMINATE Pivotal Trial Results.

Faculty:


Paul Sorajja

Paul Sorajja


Ralph Stephan von Bardeleben

Ralph Stephan von Bardeleben


Ulrich P Jorde

Ulrich P Jorde


Gilbert Tang

Gilbert Tang

This broadcast is supported by an educational grant from Abbott.

Agenda

Welcome and Introduction

Ralph Stephan von Bardeleben

What Is the Current Need for TEER Today?

Gilbert Tang

What Is the Evidence for TEER?

Paul Sorajja

TEER in Context: View From the Heart Failure Clinic

Ulrich P Jorde

TR Patient Cases: TEER or Surgery?

Ralph Stephan von Bardeleben; discussion by all

Audience Q&A and Close

Chaired by Ralph Stephan von Bardeleben

Key Learning Objectives

  • Review existing real-world and RCT evidence on tricuspid valve repair
  • Assess relative effectiveness of existing modes of treatment for severe tricuspid regurgitation
  • Identify key patient groups who may benefit from device-based valve repair over surgical repair or medical therapy
  • Recall what recent advances in the field of device-based repair means for real-world practice
  • Apply emerging data and expert guidance to current practice

Target Audience

  • Cardiologists
  • Interventional Cardiologists
  • Surgeons
  • Heart Failure Specialists

Faculty Biographies


Paul Sorajja

Paul Sorajja

Dr Paul Sorajja is an Interventional Cardiologist at the Minneapolis Heart Institute at Abbott Northwestern Hospital, where he is the Director of the Center for Valve and Structural Heart Disease.

View full profile

Ralph Stephan von Bardeleben

Ralph Stephan von Bardeleben

Prof Ralph Stephan von Bardeleben is the Head of the Center of Structural Heart Disease Interventions and the Heart Valve Center in Mainz, Germany 

View full profile

Ulrich P Jorde

Ulrich P Jorde

Dr Ulrich P. Jorde is Section Head of Heart Failure, Cardiac Transplantation & Mechanical Circulatory Support at the Montefiore Medical Center and Albert Einstein College of Medicine in New York. 

View full profile

Gilbert Tang

Gilbert Tang

Dr Gilbert Tang is Surgical Director of the Structural Heart Program at the Mount Sinai Health System and Professor of Cardiovascular Surgery at the Icahn School of Medicine at Mount Sinai in New York.

View full profile